BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) can predict the clinical response to tyrosine kinase inhibitor (TKI) therapy. However, EGFR mutations may be different in primary tumors (PT) and metastatic lymph nodes (MLN). The aim of this study was to compare EGFR mutations between PT and the corresponding MLN in NSCLC patients, and provide some guidelines for clinical treatment using TKI therapy. MATERIALS AND METHODS: A systematic review and meta-analysis was performed with several research databases. Relative risk (RR) with the 95% confidence interval (CI) were used to investigate the EGFR mutation status between PT and the corresponding MLN. A random-effects model was used. RESULTS: 9 publications involving 707 patients were included in the analysis. It was found that activation of EGFR mutations identified in PT and the corresponding MLN was 26.4% (187/707) and 19.9% (141/707), respectively. The overall discordance rate in our meta-analysis was 12.2% (86/707). The relative risk (RR) for EGFR mutation in PT relative to MLN was 1.33 (95%CI: 1.10-1.60; random-effects model). There was no significant heterogeneity between the studies (I2=5%, p=0.003). CONCLUSIONS: There exists a considerable degree of EGFR mutation discrepancy in NSCLC between PT and corresponding MLN, suggesting that tumor heterogeneity might arise at the molecular level during the process of metastasis.
BACKGROUND:Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) can predict the clinical response to tyrosine kinase inhibitor (TKI) therapy. However, EGFR mutations may be different in primary tumors (PT) and metastatic lymph nodes (MLN). The aim of this study was to compare EGFR mutations between PT and the corresponding MLN in NSCLCpatients, and provide some guidelines for clinical treatment using TKI therapy. MATERIALS AND METHODS: A systematic review and meta-analysis was performed with several research databases. Relative risk (RR) with the 95% confidence interval (CI) were used to investigate the EGFR mutation status between PT and the corresponding MLN. A random-effects model was used. RESULTS: 9 publications involving 707 patients were included in the analysis. It was found that activation of EGFR mutations identified in PT and the corresponding MLN was 26.4% (187/707) and 19.9% (141/707), respectively. The overall discordance rate in our meta-analysis was 12.2% (86/707). The relative risk (RR) for EGFR mutation in PT relative to MLN was 1.33 (95%CI: 1.10-1.60; random-effects model). There was no significant heterogeneity between the studies (I2=5%, p=0.003). CONCLUSIONS: There exists a considerable degree of EGFR mutation discrepancy in NSCLC between PT and corresponding MLN, suggesting that tumor heterogeneity might arise at the molecular level during the process of metastasis.
Authors: Vidya H Veldore; Shekar Patil; Shilpa Prabhudesai; C T Satheesh; H P Shashidhara; Naveen Krishnamoorthy; D Hazarika; R Tejaswi; Ankita Prabhudev; Radheshyam Naik; Raghavendra M Rao; B S Ajai Kumar Journal: Mol Diagn Ther Date: 2016-04 Impact factor: 4.074
Authors: Chia Ching Lee; Yu Yang Soon; Char Loo Tan; Wee Yao Koh; Cheng Nang Leong; Jeremy Chee Seong Tey; Ivan Weng Keong Tham Journal: PLoS One Date: 2019-06-19 Impact factor: 3.240
Authors: Joohae Kim; Hyo Jae Kang; Sung Ho Moon; Jong Mog Lee; Hyae Young Kim; Geon-Kook Lee; Jin Soo Lee; Bin Hwangbo Journal: Cancer Res Treat Date: 2019-03-15 Impact factor: 4.679